[HTML][HTML] Human papillomavirus vaccine against cervical cancer: Opportunity and challenge
R Wang, W Pan, L Jin, W Huang, Y Li, D Wu, C Gao… - Cancer letters, 2020 - Elsevier
Cervical cancer is one of the most common cancers threatening women's health, and the
persistent infection of high-risk human papillomavirus (HPV) is closely related to the …
persistent infection of high-risk human papillomavirus (HPV) is closely related to the …
Prophylactic and therapeutic HPV vaccines: current scenario and perspectives
Y Mo, J Ma, H Zhang, J Shen, J Chen… - Frontiers in cellular …, 2022 - frontiersin.org
Persistent human papillomavirus (HPV) infection is recognized as the main cause of cervical
cancer and other malignant cancers. Although early detection and treatment can be …
cancer and other malignant cancers. Although early detection and treatment can be …
[HTML][HTML] Therapeutic vaccines for high-risk HPV-associated diseases
Cancer is the second leading cause of death worldwide, and it is estimated that Human
papillomavirus (HPV) related cancers account for 5% of all human cancers. Current HPV …
papillomavirus (HPV) related cancers account for 5% of all human cancers. Current HPV …
The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease
AR Garbuglia, D Lapa, C Sias… - Frontiers in …, 2020 - frontiersin.org
Human papillomavirus (HPV) is the most common sexually transmitted virus. The high-risk
HPV types (ie, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are considered to be the …
HPV types (ie, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are considered to be the …
Perspectives for therapeutic HPV vaccine development
Background Human papillomavirus (HPV) infections and associated diseases remain a
serious burden worldwide. It is now clear that HPV serves as the etiological factor and …
serious burden worldwide. It is now clear that HPV serves as the etiological factor and …
Targeting persistent human papillomavirus infection
S Shanmugasundaram, J You - Viruses, 2017 - mdpi.com
While the majority of Human papillomavirus (HPV) infections are transient and cleared
within a couple of years following exposure, 10–20% of infections persist latently, leading to …
within a couple of years following exposure, 10–20% of infections persist latently, leading to …
CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer
FL Komdeur, TM Prins, S van de Wall, A Plat… - …, 2017 - Taylor & Francis
Human papilloma virus (HPV)-induced cervical cancer constitutively expresses viral E6/E7
oncoproteins and is an excellent target for T cell-based immunotherapy. However, not all …
oncoproteins and is an excellent target for T cell-based immunotherapy. However, not all …
Evolution of cancer vaccines—Challenges, achievements, and future directions
The development of cancer vaccines has been intensively pursued over the past 50 years
with modest success. However, recent advancements in the fields of genetics, molecular …
with modest success. However, recent advancements in the fields of genetics, molecular …
Therapeutic HPV vaccines
G Hancock, K Hellner, L Dorrell - … practice & research Clinical obstetrics & …, 2018 - Elsevier
Highlights•Current prophylactic vaccines protect only against infection with high risk types
HPV16 and 18.•Several new platform technologies are being applied to the development of …
HPV16 and 18.•Several new platform technologies are being applied to the development of …
[HTML][HTML] Human papillomavirus-associated head and neck cancers. Where are we now? A systematic review
M Pinkiewicz, K Dorobisz, T Zatoński - Cancer Management and …, 2022 - ncbi.nlm.nih.gov
Background Human papillomavirus targets the skin and mucous membranes, producing
benign hyperplastic lesions and precancerous and cancerous lesions. An increasing …
benign hyperplastic lesions and precancerous and cancerous lesions. An increasing …